Background. Estimating the risk of antibiotic resistance is important in selecting empiric antibiotics. We asked how the timing, number of courses, and duration of antibiotic therapy in the previous 3 months affected antibiotic resistance in isolates causing invasive pneumococcal disease (IPD).
Background. Estimating the risk of antibiotic resistance is important in selecting empiric antibiotics. We asked how the timing, number of courses, and duration of antibiotic therapy in the previous 3 months affected antibiotic resistance in isolates causing invasive pneumococcal disease (IPD).
Methods. We conducted prospective surveillance for IPD in Toronto, Canada, from 2002 to 2011. Antimicrobial susceptibility was measured by broth microdilution. Clinical information, including prior antibiotic use, was collect- 15 ed by chart review and interview with patients and prescribers.
Results. Clinical information and antimicrobial susceptibility were available for 4062 (90%) episodes; 1193 (29%) of episodes were associated with receipt of 1782 antibiotic courses in the prior 3 months. Selection for antibiotic resistance was class specific. Time elapsed since most recent antibiotic was inversely associated with resistance (cephalosporins: adjusted odds ratio [OR] per day, 0.98; 95% confidence interval [CI] , .96-1.00; P = .02; macrolides: 20 OR, 0.98; 95% CI, .96-.99; P = .005; penicillins: OR [log(days)], 0.62; 95% CI, .44-.89; P = .009; fluoroquinolones:
profile penalized-likelihood OR [log(days)], 0.62; 95% CI, .39-1.04; P = .07). Risk of resistance after exposure declined most rapidly for fluoroquinolones and penicillins and reached baseline in 2-3 months. The decline in resistance was slowest for macrolides, and in particular for azithromycin. There was no significant association between duration of therapy and resistance for any antibiotic class. Too few patients received multiple courses of the same 25 antibiotic class to assess the significance of repeat courses.
Conclusions. Time elapsed since last exposure to a class of antibiotics is the most important factor predicting antimicrobial resistance in pneumococci. The duration of effect is longer for macrolides than other classes.
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Streptococcus pneumoniae is a leading cause of illness 30 and death, with an estimated 43 500 cases and 5000 deaths annually in the United States [1] . Early adequate antimicrobial therapy is paramount to reducing morbidity and mortality [2, 3] . Because preexisting resistance to the class of antibiotic chosen for therapy is 35 associated with treatment failure and early treatment improves outcomes in severe infections, the ability to predict the likelihood of antimicrobial resistance at presentation in individual patients is crucial to the optimal choice of empiric antimicrobial therapy [4, 5] . ous studies have demonstrated the association between antimicrobial resistance and prior antibiotic use [6] [7] [8] [9] [10] . Although it is often inferred in clinical practice, the relative importance of cumulative duration of prior antibiotic therapy, number of treatment courses, and time 45 between antibiotic exposure and infection remains unclear [11] .
Insights into the clinical significance of these variables are of value to clinicians in identifying those patients with previous antibiotic exposure who are at highest risk for infection with a resistant strain of S. pneumoniae.
50
The objectives of this study were to determine the extent to which cumulative prior antibiotic exposure, number of treatment courses, and timing of prior antibiotic treatment predict antimicrobial resistance in isolates of S. pneumoniae causing invasive disease. 55 
MATERIALS AND METHODS

Population-Based Surveillance for Invasive Pneumococcal Infections
The Toronto Invasive Bacterial Diseases Network (TIBDN) is a collaboration of all hospitals, microbiology laboratories, infec-60 tion control practitioners, physicians, and public health units serving the population of metropolitan Toronto and the Regional Municipality of Peel ( population 4.1 million in 2012) that performs population-based surveillance for selected serious bacterial and viral infections [4, 8, 12] . All 25 hospitals, 65 19 laboratories, and 85 long-term-care facilities serving residents of the population area participate in this network. All invasive pneumococcal infections identified by participating laboratories from 1 January 2002 through 31 December 2011 were included in the analyses.
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Invasive pneumococcal infection was defined as illness in which S. pneumoniae was isolated from a normally sterile body site. Isolates were forwarded to the central laboratory at Mount Sinai Hospital and informed consent was obtained to collect detailed clinical data (including recent antibiotic expo-75 sure). Annual audits were conducted in each laboratory to ensure completeness of reporting. For the assessment of 30-day mortality, patients who were cured or improving at discharge before 30 days and not readmitted to the same hospital were assumed to have survived.
80
Underlying conditions predisposing to invasive pneumococcal disease (IPD) were defined as per the Canadian National Advisory Committee on Immunization [13] . Healthcareassociated infections were defined as those not present or incubating on admission [14] . 85 
Previous Antibiotic Exposure
We obtained a history of antibiotics received in the 3 months prior to the date of positive culture from patients and/or their next of kin, family physicians, other physicians identified as relevant by patients, and reviews of hospital and emergency de- 90 most recent dose <48 hours previously) for the current episode of infection when the culture yielding S. pneumoniae was obtained.
Laboratory Analysis
120
Isolates were sent to the central TIBDN laboratory at Mount Sinai Hospital (Toronto, Canada), where they were confirmed as S. pneumoniae by standard methodology, including colonial morphology on blood agar, bile solubility, susceptibility to Optochin, and AccuProbe (Gen-Probe, San Diego, California).
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Antimicrobial susceptibility testing was performed using broth microdilution in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines [15] . European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints were used for a secondary analysis assessing 130 ciprofloxacin resistance [16] . Serotyping of isolates was performed at the central study laboratory and the National Centre for Streptococcus in Edmonton, Alberta/Winnipeg, Manitoba, according to standard methodology [17] . For these analyses, we defined erythromycin, penicillin, and levo-135 floxacin resistance and ceftriaxone nonsusceptibility in accordance with CLSI guidelines (using meningitis breakpoints for penicillin and ceftriaxone), and fluoroquinolone nonsusceptibility as a ciprofloxacin minimum inhibitory concentration ≥4 mg/L.
corrected with original records. Differences in medians were analyzed using the Wilcoxon rank-sum test. Data were analyzed 145 using SAS software version 9.3 (SAS Institute, Cary, North Carolina) and are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Two-sided P values ≤.05 were considered statistically significant. Antibiotic class-specific logistic regression models were used 150 to assess the impact of time from end of antibiotic therapy, total duration of antibiotic therapy, and number of antibiotic courses on antibiotic resistance in infecting isolates (due to rare events, for fluoroquinolones, the Firth penalized-likelihood method and profile-likelihood CIs were used). Linearity was evaluated 155 graphically and variables were log-transformed if transformation improved linearity in the logit. We evaluated potential confounders if they were known from previous reports to be associated with resistance to particular antibiotic classes (macrolides: year, age, and human immunodeficiency virus infec-160 tion; fluoroquinolones: year, immunosuppressive therapy, and hospital or nursing home associated; penicillins: year, age, underlying chronic condition, alcoholism, and hospital or nursing home associated; cephalosporins: year) and were significantly associated with resistance (P ≤ .05) in bivariate analyses in 165 our dataset. Potential confounding by serotype was evaluated in all categories by grouping together 13-valent and 7-valent pneumococcal conjugate vaccine serotypes. Potential confounders were discarded if inclusion increased CIs and did not change primary effect estimates. Because failure of antimi-170 crobial therapy and relapse may be associated with preexisting antibiotic resistance in the infecting isolate, the primary analysis of impact of prior antibiotic therapy was conducted excluding relapsing patients and patients failing antimicrobial therapy. Secondary analyses were conducted including all episodes 175 with antibiotic exposure, including episodes classified as relapses but not those classified as failures, and excluding antibiotic courses whose length was imputed. Likelihood ratio tests of nested models were conducted in SAS using the %VUONG macro [18] . Profile penalized-likelihood P values were calculat-180 ed in SAS using the %FL macro [19] .
Ethics Approval
The study was approved by the research ethics boards at all participating institutions. (19.9 190 cases per 100 000 in 2011). In other age groups, the incidence of disease remained stable during the study period, averaging 2.7 cases per 100 000 among children aged 5-14 years and 4.4 cases per 100 000 in adults aged 15-64 years [20] .
Detailed were penicillin resistant, and 6% (243/4062) were nonsusceptible to ceftriaxone. Between 2002 and 2011, resistance to erythromycin increased from 14% to 32% (P < .0001), and resistance to penicillin increased from 15% to 17% (P = .0003), whereas resistance to levofloxacin remained stable. and resistance in the infecting isolate are shown in Figure 2 . Table 1 shows the time elapsed since most recent antibiotic course (same class) and cumulative duration of prior antibiotic treatment by antibiotic resistance/nonsusceptibility among those who received antibiotics. Time since most recent antibiot-235 ic course was significantly associated with resistance/nonsusceptibility in macrolides, penicillins, and cephalosporins (fluoroquinolones: P = .10). There was no significant association between cumulative days of antibiotic treatment and resistance/nonsusceptibility for any antibiotic class.
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Among those with prior antibiotic exposure, the number of courses of cephalosporins was significantly associated with increased risk of resistance/nonsusceptibility. Table 2 displays univariate ORs for antibiotic resistance/nonsusceptibility for time elapsed since most recent antibiotic course and number 245 of antibiotic courses, as well as for other potential risk factors for resistance. In multivariate analyses, more recent antibiotic treatment was significantly associated with risk of resistance/ nonsusceptibility in macrolides (P = .005), cephalosporins (P = .02), and penicillins (P = .009) (fluoroquinolones: P = .07; 250 Table 3 ). Secondary analyses including failures and relapses, excluding only failures, and excluding antibiotic courses for which the length of therapy were imputed yielded the same trends (data not shown). Secondary analysis using the EUCAST breakpoints for cipro-255 floxacin (resistance ≥2 mg/L) identified a statistically significant association between days from last antibiotic and fluoroquinolone resistance (penalized-likelihood unadjusted OR [log(days)], 0.61; 95% CI, .45-.83; P = .003), but no significant association between number of courses of fluoroquinolones (OR, 1.38; 95% CI, .49-260 3.06; P = .5), or duration of therapy and resistance (OR, 1.01; 95% CI, .98-1.03; P = .5). Secondary analysis using nonmeningitis breakpoints for penicillin identified a significant association between days from last penicillin dose and penicillin nonsusceptibility (unadjusted OR [log(days)], 0.46; 95% CI, .28-.75; P = .002), 265 but no significant association between number of courses (OR, 1.96; 95% CI, .45-8.57; P = .37) or duration of therapy and nonsusceptibility (OR, 0.99; 95% CI, .91-1.08; P= .84). Probability plots for antibiotic resistance/nonsusceptibility with regard to time since most recent antibiotic course (same 270 class) are shown in Figure 3 . For antibiotics other than macrolides, there is a rapid decrease in risk of resistance during the first month after therapy, followed by a slower but continuous decline without a clear cutoff. For macrolides, particularly azithromycin, the decrease appears to be slower and more line-275 ar. The association between resistance and prior macrolide treatment differed between azithromycin and other macrolides (likelihood ratio test, P = .01); the risks associated with prior azithromycin treatment decreased more slowly as exposures became more distant than the risks associated with exposures to 280 other macrolides (data not shown).
DISCUSSION
In prospective surveillance of IPD, we were able to confirm the association between prior antibiotic use and pneumococcal resistance. Our results suggest that the time elapsed from most re-285 cent treatment and new infection is much more important than cumulative prior antibiotic exposure. For penicillins, cephalosporins, and fluoroquinolones, resistance declines rapidly in the first month after antibiotic exposure, and by 60-90 days after the last dose of antibiotics, the probability of resistance 290 has returned to baseline population levels. For macrolides, the decline in resistance appears to be slower and more continuous.
Although a few prospective studies have examined the relationship between the details of antibiotic exposure and resistance development [21] [22] [23] , differentiating particular factors 295 related to prior antimicrobial exposure and the development of resistance has been challenging. A recent systematic review by Costelloe et al was unable to detect any studies that compared the effects of timing of antibiotic treatment, duration of therapy, and number of courses of antibiotics and resistance 300 in pneumococci [11] . In addition, none of the identified studies assessed time from the end of antibiotic therapy as a continuous variable [11] . Guillemot et al, in a study of penicillin resistance in 55 nasopharyngeal isolates of pneumococci in 54 children, only identi-305 fied resistance in children who had received longer courses and lower doses of antibiotics in the 30 days prior to culture, but the differences between longer and shorter duration and higher and lower doses of antibiotics were not statistically significant [24] . In a retrospective cohort study of factors associated with peni-310 cillin resistance in 303 pediatric and adult patients with pneumococcal bacteremia, Ruhe and Hasbun found that longer exposure to β-lactams and >1-2 courses of β-lactams, sulfonamides, and macrolides were associated with penicillin nonsusceptibility in pneumococcal isolates [25] . Neither of these 315 studies assessed time from last antibiotic exposure, and neither had adequate power to permit multivariable analysis. In studies of bacterial species other than pneumococci, Costelloe et al found that longer duration and multiple courses of antibiotic exposure were generally associated with higher 320 rates of antibiotic resistance, but results were not consistent [23, 26, 27] . The prospective study by Malhotra-Kumar et al demonstrated that azithromycin and clarithromycin resistance in oral streptococci appear to decrease with time from antibiotic exposure over a >6-month period [21] , with clarithromycin re-325 sistance rates declining more rapidly. In contrast, the study on the effect of amoxicillin exposure on resistance rates in Haemophilus influenzae by Chung et al showed that resistance rates decrease to near baseline within 12 weeks [22] . In another study of amoxicillin and urinary tract infections due to Escherichia coli, 330 Hillier et al found that longer duration, lower dose, and time from most recent antibiotic exposure were all associated with [15] , using meningitis breakpoints for penicillin resistance and ceftriaxone nonsusceptibility. Fluoroquinolone nonsusceptibility is defined as a ciprofloxacin minimum inhibitory concentration ≥4 mg/L. e OR for log(days).
f Factors associated with resistance to at least 1 specific antibiotic class in previous reports. Variables evaluated as potential confounders in class-specific analyses described in the Methods. g Presence of ≥1 underlying chronic condition predisposing to invasive pneumococcal disease as defined by the Canadian National Advisory Committee on Immunization in 2012 (as per [13] , but excluding asthma). h Presence of ≥1 immunosuppressive condition: lymphoma, hematologic malignancy, chronic renal failure, cirrhosis, previous organ transplant, asplenia, sickle cell disease, systemic lupus erythematosus, HIV infection, or those receiving chemotherapy, radiation, prednisone, or other immunosuppressive therapy.
amoxicillin resistance, with resistance returning to baseline within 1-3 months [27] . These studies suggest that decay in resistance risk after exposure to antibiotics may depend on the 335 particular antibiotic-bacterial species combination being studied.
Our results indicate that, for antibiotics other than macrolides, baseline resistance rates can be expected after 90 days from last antibiotic exposure in S. pneumoniae. After exposure 340 to macrolides, particularly azithromycin, resistance rates decrease more slowly. This may be explained by the longer plasma half-life of azithromycin (>60 hours compared with 5-7 hours for clarithromycin, 7 hours for levofloxacin, or 70 minutes for amoxicillin), leading to prolonged subtherapeutic concentra-345 tions of azithromycin and ongoing selection of resistant bacterial strains for >3 weeks after treatment [21, [28] [29] [30] [31] . That time from end of antibiotic treatment plays a role in predicting antibiotic resistance seems obvious in that the antibioticsusceptible bacterial population surviving antibiotic treatment 350 (so-called persister cells) requires time to repopulate mucosal surfaces and outnumber resistant strains with a growth disadvantage due to fitness costs of maintaining mechanisms of resistance [32] . Similarly, the relatively consistent trend toward additional antibiotic courses being associated with increased 355 risk of resistance is logical, although it is important to note that few patients received multiple courses of the same antibiotic, and the confidence limits on the estimate of the effect of numbers of courses are wide. Less intuitively, we were unable to identify any association between total duration of antibiotic 360 exposure and risk of resistance. The apparent discrepancy between the effect of number of courses and duration of therapy may occur because multiple rounds of exposure results in more effective selection for drug-resistant strains than a single, more prolonged exposure. However, as mentioned before, it is also 365 possible that, despite excluding antibiotic failures and relapses, our findings are affected by artifacts of sampling. Our study has several limitations. Sampling from 10 years in a single geographic area may limit the generalizability of our results to other settings. As discussed above, our results apply to 370 S. pneumoniae and prior antibiotic exposure to macrolides, fluoroquinolones, penicillins, and cephalosporins and may not translate to other bacterial species-antibiotic combinations. We were not able to assess the role of antibiotic dose on development of resistance [33] . Antibiotic resistance rates change 375 over time, as demonstrated for macrolide resistance in our data set. Although our multivariable models found that this did not affect the association between time from end of antibiotic exposure and bacterial resistance, this may not be true in all circumstances [21] , and relationships may differ if mechanisms 380 of resistance differ over time, or as the introduction of pneumococcal vaccination programs changes the serotype distribution of pneumococcal infections. Finally, antibiotic exposures were as defined by patients' reporting having taken them and/or physicians' reporting having written a prescription; however, not all 385 prescriptions may have been filled, patients' recall may be subject to bias, and we did not assess compliance with taking antibiotics.
In conclusion, in patients previously exposed to antibiotics who subsequently develop pneumococcal disease, the time 390 elapsed from the last treatment course is of considerable value in predicting antimicrobial resistance and the number of courses may be of value, but cumulative antibiotic exposure is not helpful. Clinicians' choices of empirical antibiotic therapy for presumptive pneumococcal infections should ideally take 395 into account the shape of declining resistance over time. Further research is needed to define relationships in other bacterial species-antibiotic combinations. Increasing the precision and detail in information collected about antibiotic exposure in studies of antibiotic resistance may help to improve clinician de-400 cision making about empiric antibiotic choices in the future. Figure 3 . Days since most recent antibiotic course and predicted probability of antibiotic resistance from antibiotic class-specific multivariable logistic regression models for 1 (solid red line) or 2 (solid blue line) antibiotic courses among cases of invasive pneumococcal disease who were exposed to antibiotics for a different episode in the 3 months prior to positive culture of Streptococcus pneumoniae, Toronto Invasive Bacterial Diseases Network, 2002-2011. Transparent colored areas (red and blue) represent 95% confidence intervals (CIs), respectively (Wald CIs for macrolides, penicillins, and cephalosporins; profile-likelihood CIs for fluoroquinolones). Macrolide plot displayed for year of infection 2011. A, Days from end of most recent penicillin course and probability of penicillin resistance. B, Days from end of most recent macrolide course and probability of erythromycin resistance. C, Days from end of most recent cephalosporin course and probability of ceftriaxone nonsusceptibility. D, Days from end of most recent fluoroquinolone course and probability of ciprofloxacin nonsusceptibility.
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